Ocuphire Pharma Investor Day Presentation Deck
P
82
VEGA-1: Nyxol+LDP Met Primary & Secondary Endpoints
61% Patients with Nyxol+LDP had ≥ 15 Letter Near Gain with Fast Onset & Durable Responses
Percent of Subjects (%)
70%
60%
50%
40%
30%
20%
10%
0%
Percent of Subjects with ≥ 15 Letters Binocular Photopic DCNVA Improvement from Baseline
Phase 2
Primary Endpoint
p=0.09
33%
16%
0
Rapid onset
of efficacy
p<0.0001
61%
14%
VEGA-1 Phase 2 Trial
0.5
p=0.003
61%
28%
1
p<0.0001
63%
Placebo (n=43)
16%
2
Time (Hours)
p=0.02
47%
21%
Nyxol+LDP (n=43)
3
p=0.02
21%
4
47%
Durable benefit
over 6 hours
p=0.06
37%
19%
Note: PP population differs from mITT by only one subject; results were essentially identical.
Source: VEGA-1 TLR Table 14.2.1.2 Percent of Subjects with Improvement From Baseline in Photopic DCNVA by Time Point (PP Population). 15 letters is 3 lines.
6
Ocuphire
PHARMAView entire presentation